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The contribution of catecholamines to the control of metabolic events occurring in mature adipocytes such as lipolysis
has been well documented. Human adipocytes express signifi-
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cant levels of ␤1-, ␤2-, and ␣2-adrenergic receptors (ARs),1
which couple positively (␤1 and ␤2) and negatively (␣2) to
adenylyl cyclase (1). Endogenous ligands, epinephrine and
norepinephrine, activate both classes of receptors (1, 2), suggesting an important role for ␣2/␤-AR balance in regulating
lipolysis and energy balance (1, 3, 4). Adipocytes from obese
humans have increased ␣2-ARs, ␣2/␤-AR ratios, and ␣2-ARmediated responses (3–9). In addition, longitudinal studies in
animal models have shown that ␣2-ARs are increased with fat
cell hypertrophy and that increased ␣2/␤-AR balance is correlated with obesity (5, 10, 11). Thus, it has been proposed that
␣2/␤-AR balance affects adipose tissue development.
Murine adipocytes differ from human adipocytes in that they
express many ␤3-ARs, in addition to ␤1- and ␤2-ARs, and very
few ␣2-ARs (1, 12). ␤3-ARs, like ␤1- and ␤2-ARs, couple positively to adenylate cyclase. In mice, ␤3-ARs are expressed
predominantly in white and brown adipocytes, where they are
thought to play an important role in regulating lipolysis and
thermogenesis (1). Surprisingly, ␤3-AR gene knockout mice
have little or no increase in body weight and only a slight
increase in body fat (13, 14). The absence of greater effects of
␤3-AR deficiency on fat stores could be due to the fact that
murine adipocytes, unlike human adipocytes, express very few
␣2-ARs (12), which if present would antagonize actions mediated by residual ␤1- and ␤2-ARs and even initiate some additional effects.
To assess the importance of ␣2/␤-AR balance in adipocytes in
vivo, we have combined gene targeting and transgenic approaches to create mice with increased ␣2/␤-AR balance in
adipose tissue. Specifically, the aP2 promoter (15) was used to
drive adipocyte-specific expression of ␣2-ARs in mice that were
either homozygous (⫺/⫺) or heterozygous (⫹/⫺) for a disrupted
␤3-AR allele. Mice with genetically altered ␣2/␤-AR balance
were then assessed for sensitivity to high fat diet-induced obesity. Of note, mice with increased ␣2/␤-AR balance developed
diet-induced obesity secondary to adipocyte hyperplasia. These
results strongly suggest that ␣2/␤-AR balance plays an important role in regulating fat mass.
MATERIALS AND METHODS

Transgenic Mice—All genetically modified animals were created and
maintained on an FVB/n inbred background and were genetically identical except for the specified genetic alterations. Creation of ␤3 ⫺/⫺
1
The abbreviations used are: AR, adrenergic receptor; kb, kilobase(s);
trans, transgenic.
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Catecholamines play an important role in controlling
white adipose tissue function and development. ␤- and
␣2-adrenergic receptors (ARs) couple positively and
negatively, respectively, to adenylyl cyclase and are coexpressed in human adipocytes. Previous studies have
demonstrated increased adipocyte ␣2/␤-AR balance in
obesity, and it has been proposed that increased ␣2-ARs
in adipose tissue with or without decreased ␤-ARs may
contribute mechanistically to the development of increased fat mass. To critically test this hypothesis, adipocyte ␣2/␤-AR balance was genetically manipulated in
mice. Human ␣2A-ARs were transgenically expressed in
the adipose tissue of mice that were either homozygous
(ⴚ/ⴚ) or heterozygous (ⴙ/ⴚ) for a disrupted ␤3-AR allele.
Mice expressing ␣2-ARs in fat, in the absence of ␤3-ARs
(␤3-AR ⴚ/ⴚ background), developed high fat diet-induced obesity. Strikingly, this effect was due entirely to
adipocyte hyperplasia and required the presence of ␣2ARs, the absence of ␤3-ARs, and a high fat diet. Of note,
obese ␣2-transgenic, ␤3 ⴚ/ⴚ mice failed to develop insulin resistance, which may reflect the fact that expanded
fat mass was due to adipocyte hyperplasia and not adipocyte hypertrophy. In summary, we have demonstrated that increased ␣2/␤-AR balance in adipocytes
promotes obesity by stimulating adipocyte hyperplasia.
This study also demonstrates one way in which two
genes (␣2 and ␤3-AR) and diet interact to influence fat
mass.
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RESULTS

To evaluate the physiologic significance of adipocyte ␣2-ARs,
we had previously generated and studied transgenic mice, on a
wild-type ␤3-AR (⫹/⫹) background, which express human ␣2AARs in white and brown fat (22) (transgene shown in Fig. 1a).
Despite the presence of abundant ␣2-AR binding sites, transgenic mice had normal body weight and fat content (data not
shown). We hypothesized that the absence of an effect of ␣2ARs on fat stores was due to the presence of abundant ␤3-ARs,
which along with ␤1- and ␤2-ARs override the inhibitory actions of transgenically expressed ␣2-ARs.
In the present study, we assessed the importance of ␣2/␤-AR
balance in adipocytes by creating ␣2-AR transgenic mice
(Tg(ADRA2A)1Lowl) on a ␤3-AR ⫺/⫺ and ⫹/⫺ background
(mice ⫺/⫺ or ⫹/⫺ for the Ardb3tm1Lowl allele) (13). The transgene employed was the aP2-promoter/human ␣2A-AR construct mentioned above (shown in Fig. 1a). As expected, mRNA
encoding human ␣2A-AR was expressed in white and brown
adipocytes, but not in liver, kidney, skeletal muscle, brain,

FIG. 1. a, schematic representation of the aP2-␣2A-AR transgene.
aP2 fatty acid-binding protein 5⬘-flanking regulatory sequence (15),
⫺5.4 kb (EcoRI) to ⫹21 base pairs (PstI), was fused to 1.4 kb of human
genomic DNA containing the human ␣2C10 gene and the splice/polyadenylation site of SV40. b, fat-specific expression of ␣2-AR transgene
mRNA in mouse tissues and isolated fat cells. Total RNA was isolated
from tissues (left) or isolated cells from white adipose tissue (right) and
was analyzed by Northern blotting using a specific 1.5-kb SV40 probe.
c, specific binding of (3H)RX-821002 to fat cell membranes incubated for
30 min at 25 °C without (total binding) or with (nonspecific binding) 10
M epinephrine (24). The maximal number of sites (Bmax) and equilibrium dissociation constant (KD) were calculated using Scatchard analysis of binding data from control (␤3 ⫺/⫺) and transgenic (␣2-trans, ␤3
⫺/⫺) samples (n ⫽ 2).

intestine, heart, or non-adipocyte cells resident within adipose
tissue (stroma-vascular fraction) (Fig. 1b). Using the ␣2-ARselective radioligand, (3H)RX-821002, few ␣2-AR binding sites
were found in membranes isolated from white adipocytes and
brown adipose tissue of ␤3 ⫺/⫺ mice, confirming that murine
adipocytes express very few ␣2-ARs (Fig. 1c). In contrast, abundant binding sites were observed in membranes isolated from
␣2-trans, ␤3 ⫺/⫺ mice (Fig. 1c). It is important to note that the
number of ␤1/␤2-ARs (91.6 ⫾ 4.0 fmol/mg of protein; n ⫽ 5)
observed in adipocytes of ␣2-trans, ␤3 ⫺/⫺ mice was not different from that found in adipocytes of ␤3 ⫺/⫺ mice (102.7 ⫾
7.5 fmol/mg of protein; n ⫽ 3) and was within the range of ␤-AR
binding sites typically observed in human fat cells (23). Moreover, the number of ␣2-AR binding sites detected in ␣2-AR
transgenic mice is comparable with that seen in human adipocytes and lower than that sometimes observed in obese human
adipocytes (4, 5, 7).
Epinephrine, an agonist for both ␤- and ␣2-ARs, stimulates
lipolysis in white adipocytes by increasing cAMP levels (1). As
predicted, the human-like ␣2/␤-AR balance obtained in ␣2trans, ␤3 ⫺/⫺ mice shifted the epinephrine concentration-response curve for stimulation of lipolysis to the right (Fig. 2a,
left panel). This effect was lost when the ␣2-AR-selective antagonist, RX-821002, was present (Fig. 2a, right panel). In
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mice, homozygous for the Ardb3tm1Lowl allele, has previously been described (13). The aP2-␣2A-AR transgene (see Fig. 1a) was constructed
by fusing mouse aP2 fatty acid-binding protein 5⬘-flanking regulatory
sequence (16), ⫺5.4 kb (EcoRI) to ⫹21 base pairs (PstI), to 1.4 kb (NcoI
to HindIII) of human genomic DNA containing the human ␣2C10 gene
(16) and the splice/polyadenylation site of SV40. Comparisons between
mice with Tg(ADRA2A)Lowl and without the ␣2-AR transgene were all
performed on littermates. Animals were group-housed at 24 °C, had
free access to food and water, and were handled in accordance with the
principles and guidelines established by the National Institutes of
Health. Where indicated, mice were weaned at the age of 3 weeks onto
low fat (#D12450) or high fat (#D12451) diets (Research Diets, New
Brunswick, NJ). Diets were matched for protein content and had the
following composition (as a % of total calories): low fat diet (10% fat,
70% carbohydrate, and 20% protein); high fat diet (45% fat, 35% carbohydrate, and 20% protein).
Radioligand Binding Assays—Specific binding of the ␣2-adrenergic
receptor antagonist (3H)RX-821002 to fat cell membranes was determined after 30 min of incubation at 25 °C without (total binding) or
with (nonspecific binding) 10 M epinephrine (12). The maximal number of ␣2-AR binding sites (Bmax) and equilibrium dissociation constants
(KD) were calculated using Scatchard analysis of saturation binding
data.
Lipolysis—The in vitro lipolytic response of isolated white fat cells to
epinephrine without or with 10 M selective ␣2-adrenergic receptor
antagonist RX-821002 was measured. Adipocytes were isolated, and
lipolysis was measured as described previously (12). The in vivo lipolytic response of conscious overnight-fasted mice was measured 10 min
after a 0.1 mg/kg epinephrine intraperitoneal injection by non-esterified
fatty acid blood levels.
mRNA Analyses—Total RNA was isolated using a Brinkman homogenizer and RNA STAT-60 solution (Tel-Test “B,” Inc., Friendswood,
TX). ␣2-AR transgene mRNA was analyzed by Northern blotting using
either a specific 1.5-kb SV40 probe or 1.2-kb ␣2C10 probe. UCP1 mRNA
levels were analyzed by Northern blotting using a specific mouse 0.3-kb
UCP1 cDNA probe.
Oxygen Consumption—Oxygen consumption was measured in
10⫺week-old mice using the OXYMAX system 4.93 (Colombus Instruments, Colombus, OH), with a settling time of 100 s, a measuring time
of 50 s, and with the reference as room air. The animals were placed in
four 0.3-liter chambers at thermal neutrality (30 °C).
Assessment of Fat Stores—The measurement of total body lipid content was performed as described previously (17, 18). Fat cell size and fat
cell number per fat depot were determined in perigonadal fat samples
using the Hirsch and Gallian method (19) of lipid extraction, osmium
tetroxide fixation, and Coulter Counter analysis. Histological determinations were performed as described previously (microscopic assessment of fat cell size; 600 cells per depot quantified in paraffin-embedded, inguinal fat pad sections from female mice) (20, 21).
Circulating Blood Metabolites and Hormones—Whole blood was collected and analyzed for blood glucose levels (One Touch blood glucose
meter, Lifescan Inc., Milpitas, CA). Serum was isolated and assayed for
non-esterified fatty acids (NEFA C kit, Wako Pure Chemical Industries,
Ltd.), insulin, and leptin (mouse insulin or leptin kit, Linco Research
Inc., St. Louis, MO).
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addition, the ␣2-AR agonist, UK14304, inhibited lipolysis in a
concentration-dependent fashion (data not shown). Finally, displacement of (3H)RX-821002 binding by epinephrine in ␣2trans, ␤3 ⫺/⫺ fat cell membranes (data not shown) gave the
expected shallow competition curve with high and low affinity
components (KiH, 0.81 nM; KiL, 30 nM) as classically described
in human fat cells (7). These results demonstrate that ␣2-ARs
in transgenic adipocytes are coupled to Gi protein. As expected,
the in vivo circulating free fatty acid response to a single
injection of epinephrine was blunted in ␣2-trans, ␤3 ⫺/⫺ mice
(Fig. 2b). These in vitro and in vivo studies demonstrate that
␣2-ARs in white adipocytes of ␣2-trans, ␤3 ⫺/⫺ mice functionally antagonize epinephrine-induced stimulation of lipolysis
(similar to what has been observed using isolated human white
adipocytes) (6).
The effects of ␣2-AR expression on brown fat function were
assessed. Cold exposure induces sympathetic nervous stimulation of UCP1 gene expression and thermogenesis in brown
adipocytes, and this response plays an important role in maintaining the body temperature of mice (25–27). Compared with
wild-type mice, ␤3 ⫺/⫺ mice had impaired induction of UCP1
mRNA and decreased body temperature following acute cold
exposure (Fig. 2c). These responses were not inhibited further
by expression of ␣2-ARs in brown fat (␣2-trans, ␤3 ⫺/⫺ mice)
(Fig. 2c). In addition, a single injection of epinephrine stimulated energy expenditure to a similar degree in ␤3 ⫺/⫺ mice
and ␣2-trans, ␤3 ⫺/⫺ mice (Fig. 2d). These studies suggest that
brown adipocyte function, in contrast to white adipocyte func-

tion, is not impaired by transgenic expression of ␣2-ARs.
To assess effects of ␣2/␤-AR balance on body weight and total
body lipid content, ␤3 ⫺/⫺ mice and ␣2-trans, ␤3 ⫺/⫺ mice
were fed high fat and low fat diets from age 3 weeks to 20
weeks. When fed a low fat diet, body weights were similar in ␤3
⫺/⫺ mice and ␣2-trans, ␤3 ⫺/⫺ mice (Fig. 3a). In contrast,
when fed a high fat diet, body weights were markedly greater
in ␣2-trans, ␤3 ⫺/⫺ mice compared with ␤3 ⫺/⫺ mice (Fig. 3b).
Of interest, the effect of ␣2-AR expression on body weight was
greater in female mice. A second line of ␣2-AR transgenic mice
was created which, compared with the first line, expressed 50%
lower levels of human ␣2-AR mRNA transcripts in white and
brown fat (data not shown). Despite this lower level of expression, high fat diet-induced obesity was also observed in the
second line of ␣2-AR transgenic mice on a ␤3-AR ⫺/⫺ background (Fig. 3c).
To assess the contribution of ␤3-AR deficiency in mediating
the positive effect of ␣2-AR expression on high fat diet-induced
obesity, ␣2-trans, ␤3 ⫺/⫺ mice (line 1) were crossed with wildtype mice (⫹/⫹ for the ␤3-AR allele). All offspring were ⫾ for
the ␤3-AR allele, whereas approximately 50% of offspring were
positive for the ␣2-AR transgene. As above, mice were fed a
high fat diet from age 3 weeks to 20 weeks. In contrast to
studies performed using ␤3-AR ⫺/⫺ mice, ␣2-AR expression
failed to promote high fat diet-induced obesity in ␤3-AR ⫹/⫺
mice (Fig. 3d). Thus, development of high fat diet-induced
obesity required both the presence of ␣2-ARs in fat and the
absence of ␤3-ARs.
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FIG. 2. a, in vitro lipolytic response of isolated white fat cells to epinephrine without (left) or with (right) 10 M selective ␣2-adrenergic receptor
antagonist RX-821002. Adipocytes were isolated, and lipolysis was measured as described previously (24). Values are the mean ⫾ S.E. from six
experiments. b, In vivo lipolytic response of control (␤3 ⫺/⫺) or transgenic (␣2-trans, ␤3 ⫺/⫺) overnight-fasted mice 10 min after a 0.1 mg/kg
epinephrine intraperitoneal injection. Basal values were 1.11 ⫾ 0.13 and 1.12 ⫾ 0.11 mM, respectively; *, p ⬍ 0.05 when compared with basal (n ⫽
6). c, time course of UCP1 mRNA levels (left) and body temperature (right) adaptation during a 4 °C exposure in wild type, control (␤3 ⫺/⫺), or
transgenic (␣2-trans, ␤3 ⫺/⫺) fed mice. UCP1 mRNA levels were analyzed by Northern blotting using a specific mouse 0.3-kb UCP1 cDNA probe
and expressed as a percent of time zero. *, p ⬍ 0.05 when compared with basal (n ⫽ 6). d, effect of 0.1 mg/kg intraperitoneal epinephrine on O2
consumption measured 10 min after injection in control (␤3 ⫺/⫺) or transgenic (␣2-trans, ␤3 ⫺/⫺) fed mice. Basal values were 39.9 ⫾ 2.3 and 38.3 ⫾
2.4 ml/kg/min, respectively; *, p ⬍ 0.05 (unpaired, 2-tailed t test) when compared with basal (n ⫽ 6). All results are expressed as the mean ⫾ S.E.
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FIG. 3. Body weight time course of female (left) and male
(right) mice (n ⴝ 8 –11; mean ⴞ S.E.; *, p < 0.01; unpaired, 2-tailed
t test). a, low fat diet, ␤3 ⫺/⫺ background, with or without the ␣2-AR
transgene (line 1). b, high fat diet, ␤3 ⫺/⫺ background, with or without
the ␣2-AR transgene (line 1). c, high fat diet, ␤3 ⫺/⫺ background, with
or without the ␣2-AR transgene (line 2). d, high fat diet, ␤3 ⫹/⫺
background, with or without the ␣2-AR transgene (line 1).

Further study of ␤3 ⫺/⫺ mice and ␣2-trans, ␤3 ⫺/⫺ mice fed
a high fat diet demonstrated that female mice expressing ␣2ARs had a 2.7-fold increase in total body lipid content and 2.4and 3.4-fold increases in perigonadal and inguinal fat pad
weights, respectively (Fig. 4a). Male mice expressing ␣2-ARs
had a 1.5-fold increase in total body lipid content and 1.5- and
1.7-fold increases in perigonadal and inguinal fat pad weights,
respectively (Fig. 4b). These results demonstrate that increased body weight in high fat diet-fed ␣2-AR-expressing ␤3
⫺/⫺ mice is due to an expansion of total body fat mass.
To assess the contribution of adipocyte hyperplasia versus
hypertrophy to increased adipose tissue mass, the Hirsch and
Gallian method (19) of lipid extraction and osmium tetroxide
fixation were used to determine fat cell size and number in the

In the present study we have used genetic engineering in
mice to test the hypothesis that ␣2/␤-AR balance in adipocytes
is an important determinant of total body fat stores. By creating mice that have a “human-like” pattern of AR expression in
fat (predominance of ␣2- over ␤1- and ␤2-ARs and absence of
␤3-ARs), we have demonstrated that increased ␣2/␤-AR balance promotes high fat diet-induced obesity in mice. Notably,
the development of obesity requires the presence of ␣2-ARs on
adipocytes, the absence of ␤3-ARs, and a high fat diet, suggesting an important interaction between two genes (␣2 and ␤3AR) and diet on the regulation of total body fat stores.
The present study clearly indicates that increased ␣2/␤-AR
balance in adipocytes promotes high fat diet-induced obesity.
However, the mechanism for this effect has yet to be established. Three possibilities are worthy of further discussion.
Firstly, impaired sympathetic activation of lipolysis in white
adipocytes could lead to increased accumulation of triglyceride.
Secondly, impaired sympathetic activation of thermogenesis in
brown adipose tissue could cause decreased energy expenditure
and, consequently, positive energy balance. Thirdly, impaired
sympathetic activation of white adipocytes could cause, via
mechanisms to be discussed below, hyperplasia of white adipose tissue. Detailed analysis of ␣2-trans, ␤3 ⫺/⫺ mice indicates that the first and second possibilities are less likely to be
true. Obesity due to either impaired lipolysis or decreased
energy expenditure would be expected to cause adipocyte enlargement, a feature common to nearly all models of obesity
(30, 31). In the case of ␣2-trans, ␤3 ⫺/⫺ mice, obesity was due
entirely to adipocyte hyperplasia. In addition, brown fat function appeared not to be impaired in ␣2-trans, ␤3 ⫺/⫺ mice.
Thus, the fact that enlarged fat mass in ␣2-trans, ␤3 ⫺/⫺ mice
is due entirely to the proliferation of small adipocytes strongly
suggests that high ␣2/␤-AR balance promotes adipocyte
hyperplasia.
The form of obesity observed in high fat diet-fed ␣2-trans, ␤3
⫺/⫺ mice is atypical because it is due entirely to adipocyte
hyperplasia. In this regard, these animals do not represent
murine models of “typical” human obesity (31). Obesity in humans as well as rodents is nearly always associated with adipocyte hypertrophy and hyperplasia. Typically, adipocyte hypertrophy occurs early during the development of obesity. It
has been speculated that adipocytes, upon reaching a “critical
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perigonadal depots of high fat diet-fed mice. Fat cell size was
decreased in ␣2-trans, ␤3 ⫺/⫺ mice by 25% in females (not
statistically significant) and by 32% in males. Fat cell number,
on the other hand, was markedly increased in ␣2-trans, ␤3 ⫺/⫺
mice 3.5-fold in females and 1.7-fold in males. These findings
indicate that expansion of adipose tissue mass in 20-week-old
high fat diet-fed ␣2-trans, ␤3 ⫺/⫺ mice is due to adipocyte
hyperplasia and not to an increase in fat cell size. This observation was confirmed using an alternative method of fat cell
size determination (20, 21) (microscopic assessment of fat cell
size; 600 cells per depot quantified in paraffin-embedded, inguinal fat pad sections from female mice) (data not shown).
Obesity is usually associated with elevated blood levels of
glucose, insulin, free fatty acids, and leptin. It has been proposed that these features of obesity are due to the presence of
enlarged adipocytes (28, 29). However, as shown in Fig. 4c,
obese ␣2-trans, ␤3 ⫺/⫺ mice, have normal blood glucose and
insulin levels and reduced fatty acid levels, which is in agreement with hyperplasia without changes in adipocyte size observed in these mice. The weak but significant rise in blood
leptin levels is not associated with increased leptin mRNA
expression in adipose tissue (data not shown) but probably with
the higher number of adipocytes.
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fat cell size,” release a factor that promotes adipocyte hyperplasia; however, the identity of this hypothetical factor is unknown. The present study indicates that ␣2-trans, ␤3 ⫺/⫺ mice
have a primary disturbance in adipocyte hyperplasia, and on
that basis these animals provide a novel means to explore
pathways controlling adipocyte hyperplasia. One candidate signal for stimulating adipocyte hyperplasia in ␣2-trans, ␤3 ⫺/⫺
mice is lysophosphatidic acid, a bio-active phospholipid. It has
previously been shown that stimulation of ␣2-ARs causes release of lysophosphatidic acid leading to proliferation of preadipocytes (34). Further studies will be required to determine
whether lysophosphatidic acid is the mediator of this effect.
Obese ␣2-trans, ␤3 ⫺/⫺ mice, on the other hand, have an
increased number of small adipocytes, normal blood glucose
and insulin levels, reduced free fatty acid levels, and minimally
elevated leptin levels (Fig. 4c). In this regard, ␣2-trans, ␤3 ⫺/⫺
mice resemble rodents treated with thiazolidinediones (32, 33),
agonists of peroxisome proliferator-activated receptor-␥. Based
upon this similarity, it is possible that increased ␣2/␤-AR balance in adipocytes somehow leads to activation of peroxisome
proliferator-activated receptor-␥, possibly through generation
of PPAR␥ ligands.
High fat diet-fed ␣2-trans, ␤3 ⫺/⫺ mice develop an obesity
that is characterized by an increase in both adipocyte number
and lipid storage without any increase in fat cell size. The
findings suggest that, when fed a high fat diet, ␣2-trans, ␤3
⫺/⫺ mice develop obesity through two mechanisms: (i) an increase in fat cell number due to increased preadipocyte recruitment and (ii) an increase in the ability to store lipids due to
impaired epinephrine-stimulated lipolytic activity. If increased
lipid storage was not present, then average adipocyte size

would have been decreased by an amount reciprocal to the
increase in fat cell number. Because this was not the case, it
must be assumed that lipid storage was also increased, an
effect presumably mediated by ␣2-AR-induced antilipolytic activity, potentiated by the absence of ␤3-ARs. Thus, the increased fat mass in ␣2-trans, ␤3 ⫺/⫺ mice appears to be due to
both preadipocyte recruitment and increased lipid storage in
the newly recruited adipocytes.
Brown adipocyte function appears not to have been impaired
by transgenic expression of ␣2-ARs in ␤3 ⫺/⫺ mice. This assessment is based upon the observation that cold exposureinduced changes in UCP1 mRNA in brown fat and body temperature as well as epinephrine-induced effects on whole body
oxygen consumption were not impaired in ␣2-trans, ␤3 ⫺/⫺
mice compared with ␤3 ⫺/⫺ control mice. This raises the possibility that ␣2-ARs in brown adipocytes were not negatively
coupled to adenylate cyclase. The reason for such failure of
coupling in brown adipocytes, but not white adipocytes, is presently unknown.
In summary, the present study clearly demonstrates that
increased ␣2/␤-AR balance in adipose tissue promotes diet induced obesity. These findings suggest that increased ␣2/␤-AR
balance, which is frequently observed in human obesity (3–9),
has physiologic significance in the generation of adipocyte hyperplasia and the obese state. Identification of the biochemical
mechanism by which ␣2/␤-AR balance and high fat diet promote adipocyte hyperplasia will focus on the possible roles of
lysophosphatidic acid and peroxisome proliferator-activated receptor-␥. ␣2-trans, ␤3 ⫺/⫺ mice should provide a unique opportunity to explore the mechanisms by which expansion of
adipose tissue mass is regulated.
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FIG. 4. Assessment of fat stores and
blood parameters in 20-week-old
high fat diet-fed mice. a and b, total
body lipid, fat pad weights, and fat cell
size and number in female (a) and male
(b) mice with (␣2-trans, ␤3 ⫺/⫺) or without (␤3 ⫺/⫺) the ␣2-AR transgene (n ⫽
8 –11; mean ⫾ S.E.; *, p ⬍ 0.05; **, p ⬍
0.01; unpaired, 2-tailed t test). c, blood
parameters (whole blood glucose, serum
free fatty acids (FFAs), insulin, and leptin) in mice with (␣2-trans, ␤3 ⫺/⫺) or
without (␤3 ⫺/⫺) the ␣2-AR transgene
(n ⫽ 8 –11; mean ⫾ S.E.; *, p ⬍ 0.05; **,
p ⬍ 0.01; unpaired, 2-tailed t test).
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9. Mauriège, P., Marette, A., Atgié, C., Bouchard, C., Thériault, G., Bukowiecki,
L. K., Marceau, P., Biron, S., Nadeau, A., and Després, J. P. (1995) J. Lipid
Res. 36, 672– 684
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13. Susulic, V. S., Frederich, R. C., Lawitts, J., Tozzo, E., Kahn, B. B., Harper,
M. E., Himms-Hagen, J., Flier, J. S., and Lowell, B. B. (1995) J. Biol. Chem.
270, 29483–29492
14. Revelli, J. P., Preitner, F., Samec, S., Muniesa, P., Kuehne, F., Boss, O.,
Vassalli, J. D., Dulloo, A., Seydoux, J., Giacobino, J. P., Huarte, J., and Ody,
C. (1997) J. Clin. Invest. 100, 1098 –1106
15. Ross, S. R., Graves, R. A., Greenstein, A., Platt, K. A., Shyu, H. L., Mellovitz,
B., and Spiegelman, B. M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,
9590 –9594

16. Kobilka, B. K., Matsui, H., Kobilka, T. S., Yang-Feng, T. L., Francke, U.,
Caron, M. G., Lefkowitz, R. J., and Regan, J. W. (1986) Science 238,
650 – 656
17. Salmon, D. M., and Flatt, J. P. (1985) Int. J. Obes. 9, 443– 449
18. Hamann, A., Flier, J. S., and Lowell, B. B. (1996) Endocrinology 137, 21–29
19. Hirsch, J., and Gallian, E. (1968) J. Lipid Res. 9, 110 –119
20. Sjostrom, L., Bjorntorp, P., and Vrana, J. (1971) J. Lipid Res. 12, 521–530
21. Cinti, S., Eberbach, S., Castellucci, M., and Accili, D. (1998) Diabetologia 41,
171–177
22. Soloveva, V., Graves, R. A., Spiegelman, B. M., and Ross, S. R. (1994) J. Cell.
Biochem. 18, 172
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